Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Eye (Lond). 2012 May;26(5):630-9. doi: 10.1038/eye.2012.28. Epub 2012 Feb 24.
Non-infectious vasculitides comprise a large number of diseases. Many of these diseases can cause inflammation within the orbit and a clinical presentation, which mimics numerous other processes. Orbital disease can often be the initial presentation of a systemic process and early diagnosis can help prevent long-term, potentially fatal consequences. The evaluation and treatment of non-infectious orbital vasculitides are often complicated and require a thorough understanding of the disease and underlying systemic associations. The long-term prognosis visually and systemically must be weighed against the risks and benefits of the treatment regimen. A large variety of corticosteroid formulations currently exist and are the mainstay of initial treatment. Traditional steroid-sparing immunosuppressive agents are also an important arsenal against these vasculitides. Recently, a new class of drugs called biologics, which target the various mediators of the inflammation cascade, may potentially provide more effective and less toxic treatment. This review aims to synthesize the current literature on non-infectious orbital vasculitides.
非传染性血管炎包括大量疾病。其中许多疾病可引起眼眶内炎症和类似于许多其他过程的临床表现。眼眶疾病通常可作为全身过程的初始表现，早期诊断有助于预防长期的、潜在致命的后果。非传染性眶血管炎的评估和治疗通常较为复杂，需要深入了解疾病和潜在的全身性关联。必须权衡长期预后对视力和全身的影响，以及治疗方案的风险和益处。目前存在多种皮质类固醇制剂，是初始治疗的主要方法。传统的类固醇保眼免疫抑制剂也是对抗这些血管炎的重要武器。最近，一类称为生物制剂的新型药物被开发出来，这些药物靶向炎症级联反应的各种介质，可能提供更有效和毒性更小的治疗方法。本综述旨在综合非传染性眶血管炎的现有文献。
